Victory Capital Management
LOGC

Victory Capital Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Victory Capital Management’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,819
Closed -$29K – 3536
2020
Q1 		$29K Buy
5,819
+2,819
+94% +$21.9K ﹤0.01% 2697
2019
Q4 		$22K Sell
3,000
-3,200
-52% -$28.9K ﹤0.01% 2615
2019
Q3 		$67K Buy
6,200
+3,200
+107% +$34.2K ﹤0.01% 2572
2019
Q2 		$39K Hold
3,000
– – ﹤0.01% 1762
2019
Q1 		$30K Hold
3,000
– – ﹤0.01% 1731
2018
Q4 		$31K Buy
+3,000
New +$36.2K ﹤0.01% 1726

Other funds holding LOGC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Victory Capital Management's LOGC Position: Q2 2020 in Review

Victory Capital Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2020, closing a stake of 5,819 shares — an estimated $29K sold.

Victory Capital Management first reported a position in LOGC in Q4 2018 and held it in 6 quarters. The position peaked at $67K in Q3 2019. 43 funds tracked by Wall St. Rank hold LOGC as of Q2 2020.

  • Victory Capital Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 5,819 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $29K.
  • Victory Capital Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 6 quarters.
  • Victory Capital Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $67K in Q3 2019.
  • 43 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.